Cargando…

Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the fourth most frequent cause of cancer-related mortality worldwide. While ablation, resection and orthotopic liver transplantation are indicated at an early stage of the disease, Sorafenib (Sfb) is the current most administrated first-line treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contreras, Laura, Rodríguez-Gil, Alfonso, Muntané, Jordi, de la Cruz, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909169/ https://www.ncbi.nlm.nih.gov/pubmed/35267509 http://dx.doi.org/10.3390/cancers14051204

Ejemplares similares

Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer
por: González, Raúl, et al.
Publicado: (2020)

Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
por: López-Grueso, María José, et al.
Publicado: (2019)

Modulation of Autophagy by Sorafenib: Effects on Treatment Response
por: Prieto-Domínguez, Nestor, et al.
Publicado: (2016)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Synthesis and Antitumor Activity of Triazole-Containing Sorafenib Analogs
por: Ye, Wenjing, et al.
Publicado: (2017)

Design, synthesis, and bioactivity evaluation of antitumor sorafenib analogues
por: Zhou, Shiyang, et al.
Publicado: (2018)

Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation
por: Chung, Yong-Kyu, et al.
Publicado: (2018)

Corrigendum to “Downregulation of Thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer” [Redox Biol. 34 (2020) 101528]
por: González, R., et al.
Publicado: (2023)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells
por: Chiu, Chien-Ming, et al.
Publicado: (2018)

Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells
por: Chen, Chi-Yuan, et al.
Publicado: (2020)

The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent
por: Tang, Ke, et al.
Publicado: (2014)

Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
por: Wu, Man, et al.
Publicado: (2018)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
por: Bort, Alicia, et al.
Publicado: (2017)

ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
por: Gao, Xudong, et al.
Publicado: (2019)

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma
por: Deng, Lifen, et al.
Publicado: (2013)

Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017)

Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies
por: Navarro-Villarán, Elena, et al.
Publicado: (2016)

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015)

Antitumor Activity and Its Properties of Eubacterium lentum
por: Morinaga, Shinich, et al.
Publicado: (1988)

miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: de la Cruz-Ojeda, Patricia, et al.
Publicado: (2022)

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

Preclinical development of CD126 CAR-T cells with broad antitumor activity
por: Mishra, Ameet K., et al.
Publicado: (2021)

Complete response for advanced liver cancer during sorafenib therapy: Case Report
por: Sacco, Rodolfo, et al.
Publicado: (2011)

Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer
por: Kim, Do Hyung, et al.
Publicado: (2012)

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
por: Devapatla, Bharat, et al.
Publicado: (2015)

Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance
por: Lei, Meng, et al.
Publicado: (2019)

The Role of Non-Coding RNAs in Autophagy During Carcinogenesis
por: de la Cruz-Ojeda, Patricia, et al.
Publicado: (2022)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
por: Sangro, Bruno, et al.
Publicado: (2012)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib
por: Zhang, Rui, et al.
Publicado: (2019)

Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
por: Moghadam, Ebrahim Rahmani, et al.
Publicado: (2020)

Synthesis of Oleanolic Acid-Dithiocarbamate Conjugates and Evaluation of Their Broad-Spectrum Antitumor Activities
por: Tang, Liyao, et al.
Publicado: (2023)

Is the Antitumor Property of Trypanosoma cruzi Infection Mediated by Its Calreticulin?
por: Ramírez-Toloza, Galia, et al.
Publicado: (2016)

Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties
por: Carlisi, Daniela, et al.
Publicado: (2022)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53
por: Omar, Hany A., et al.
Publicado: (2016)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vdogpnjdtd8jjivhino5dpej94